G31.0 Frontotemporal dementia

Name of the Condition

• Frontotemporal dementia

Summary

Frontotemporal dementia (FTD) is a group of disorders characterized by progressive degeneration of the frontal and temporal lobes of the brain. This leads to changes in behavior, personality, and language, with symptoms varying based on the specific subtype. FTD typically presents in midlife and progresses over time, affecting daily functioning.

Causes

The exact cause of FTD is often unknown, but it is frequently linked to abnormal accumulation of proteins (such as tau or TDP-43) in brain cells. Genetic factors play a role in some cases, with mutations in specific genes (e.g., MAPT, GRN, C9orf72) associated with familial forms. Sporadic cases may arise from a combination of genetic and environmental influences.

Risk Factors

• Age: Most commonly diagnosed between 45 and 65 years.
• Family history: A first-degree relative with FTD increases risk.
• Genetic mutations: Inherited mutations in certain genes (e.g., MAPT, GRN) are strong risk factors.
• Sex: Slightly more common in males for some subtypes.

Symptoms

• Behavioral changes: Disinhibition, apathy, or socially inappropriate actions.
• Language difficulties: Impaired speech production or comprehension (aphasia).
• Executive dysfunction: Poor judgment, planning, or problem-solving.
• Motor symptoms: Muscle weakness, rigidity, or tremors (in some subtypes).
• Emotional blunting: Reduced empathy or emotional responsiveness.

Diagnosis

Diagnosis involves a combination of clinical evaluation, neuropsychological testing, and imaging (MRI/CT) to assess brain atrophy. Biomarker testing (e.g., CSF analysis) or genetic testing may be used to support the diagnosis, especially in familial cases. Exclusion of other conditions (e.g., Alzheimer’s disease) is critical.

Treatment Options

• Symptomatic management: Medications (e.g., SSRIs) for behavioral symptoms; speech therapy for language deficits.
• Supportive care: Occupational therapy to maintain daily function; caregiver education.
• Clinical trials: Participation in research for emerging therapies targeting underlying pathology.

Prognosis and Follow-Up

FTD is progressive, with an average survival of 6–8 years after symptom onset. Regular follow-up with neurologists or geriatric specialists is essential to monitor disease progression, adjust treatments, and address caregiver needs. Palliative care may be considered in advanced stages.

Complications

• Severe cognitive and functional decline requiring full-time care.
• Increased risk of infections (e.g., pneumonia) due to swallowing difficulties.
• Emotional distress for patients and caregivers.
• Nutritional deficiencies from eating difficulties.

Lifestyle & Prevention

• Cognitive stimulation: Engaging in mentally challenging activities may support function.
• Physical activity: Regular exercise to promote overall health.
• Social interaction: Maintaining social connections to reduce isolation.
• Healthy diet: Nutrient-rich foods to support brain health (no specific preventive diet is proven).

When to Seek Professional Help

Seek evaluation if there are persistent changes in behavior, language, or personality that interfere with daily life. Early diagnosis allows for better management and planning. Consult a neurologist or geriatrician if symptoms worsen or new issues arise.

Tips for Medical Coders

Document the specific subtype of FTD (e.g., behavioral variant, primary progressive aphasia) when available, as this may impact coding specificity. Ensure clinical documentation supports the diagnosis, including symptom onset, progression, and any genetic testing results. Code G31.0 is appropriate for frontotemporal dementia without further specification; additional codes may be needed for associated symptoms or complications.